主页 » 关于不列颠哥伦比亚省 » 中国台湾

不列颠哥伦比亚省与中国台湾

中国台湾的地理位置使其有可能成为新进入更广泛亚洲市场的企业的区域枢纽，更容易进入东亚和东南亚市场并进行分销。中国台湾是全球技术供应链中的关键枢纽，具有高度创新性，在专利申请中位列榜首。中国台湾还拥有良好的基础设施和较高的劳动力受教育程度，对国际贸易非常开放。

贸易与投资亮点

中国台湾和加拿大正在进行讨论，以促进供应链弹性和商业机遇，并加强正在进行的科学、技术和创新、教育、本地事务和绿色经济方面的合作。
中国台湾计划在未来参与更多的贸易协定，为贸易开辟更多的市场和机遇。
通过加拿大的印度-太平洋战略，加拿大将与现有合作伙伴——澳大利亚、新西兰和中国台湾——以及这些参与经济体的原住民合作，通过实施原住民经济和贸易合作安排 (IPETCA) 来支持原住民的经济赋权。

中国台湾概览

货币数字以美元为单位

外国投资者和 B.C. 省出口商的机会

农业食品、海鲜

Taiwan imports most of its food supply. The import of seafood products has grown substantially in recent years, creating significant opportunities for B.C.’s high-quality Agrifood and Seafood products in Taiwan. Vegetarian food and plant-based protein products are likely to find success in Taiwan due to the high rate of vegetarianism in the population.

清洁技术和清洁能源

B.C.’s advantages in cleantech research pairs naturally with Taiwan’s expertise in high-tech manufacturing, to help transform designs and concepts into tangible, marketable products. As Taiwan phases out its nuclear power program and decreases oil and coal consumption, the demand for LNG and renewable energy will grow significantly. B.C. is well-positioned to be a valuable partner to Taiwan, as it transitions its energy supply both through LNG exports and the clean energy technologies over the longer term. Hydrogen fuel cell technology, as a renewable source of energy, is also highly attractive as Taiwan attempts to meet 2050 emissions targets.

ICT

Taiwan is a major international player for semi-conductors and integrated circuits. Government policies prioritize innovation and developing the tech sector. There are many opportunities to be found in segments involving the Internet of Things (IOT), Artificial Intelligence (AI), ICT, agritech, online gaming, fintech, digital health, smart manufacturing, and smart transportation.

生命科学

Taiwan has been investing in its biotech sector since the 1980s. In 2021, the government amended the Development of Biotech and New Pharmaceutical Industry Act with the aim of generating opportunities in the biotechnology sector by attracting greater investment.

Taiwan’s pharmaceutical companies act mostly as Contract Development & Manufacturing Organizations (CDMO) and are historically strong in the generic drugs development and manufacturing.

Areas that present significant opportunities for B.C. firms include pharmaceutical products, medical devices and instruments, and health services, such as conducting clinical trials, licencing new intellectual property, and regulatory approval consultancy.